Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

PURPOSE: Achievement of deep molecular response with a tyrosine kinase inhibitor in patients with chronic myeloid leukemia (CML) is required to attempt discontinuation of therapy in these patients. The current subanalysis from the Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-...

Descripción completa

Detalles Bibliográficos
Autores principales: Giles, Francis J., Rea, Delphine, Rosti, Gianantonio, Cross, Nicholas C. P., Steegmann, Juan Luis, Griskevicius, Laimonas, le Coutre, Philipp, Coriu, Daniel, Petrov, Ljubomir, Ossenkoppele, Gert J., Mahon, Francois-Xavier, Saussele, Susanne, Hellmann, Andrzej, Koskenvesa, Perttu, Brümmendorf, Tim H., Gastl, Gunther, Castagnetti, Fausto, Vincenzi, Beatrice, Haenig, Jens, Hochhaus, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504128/
https://www.ncbi.nlm.nih.gov/pubmed/28364360
http://dx.doi.org/10.1007/s00432-017-2402-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504128/
https://www.ncbi.nlm.nih.gov/pubmed/28364360
http://dx.doi.org/10.1007/s00432-017-2402-x

Ejemplares similares